BeOne Medicines (ONC) Cash & Equivalents (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Cash & Equivalents of $4.8 billion for Q1 2026, up 90.42% year-over-year from $2.5 billion in Q1 2025, and up 5.37% quarter-over-quarter from $4.5 billion in Q4 2025.
BeOne Medicines (ONC) Cash & Equivalents (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Cash & Equivalents for 12 consecutive years, with $4.8 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 90.42% year-over-year to $4.8 billion; the TTM figure through Mar 2026 stood at $4.8 billion (up 90.42% YoY), while the FY2025 annual figure was $4.5 billion, up 73.08% from the prior year.
- Cash & Equivalents rose to $4.8 billion in Q1 2026 per ONC's latest filing, from $4.5 billion in the prior quarter.
- Across five years, Cash & Equivalents topped out at $4.8 billion in Q1 2026 and bottomed at $191000.0 in Q3 2022.
- Historically, Cash & Equivalents has averaged $3.0 billion across 5 years, with a median of $3.1 billion in 2023.
- Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 99.99% — and 2023, when it soared 1605835.08%.
- BeOne Medicines' Cash & Equivalents stood at $3.9 billion in 2022, then declined by 18.03% to $3.2 billion in 2023, then fell by 17.16% to $2.6 billion in 2024, then surged by 73.08% to $4.5 billion in 2025, then climbed by 5.37% to $4.8 billion in 2026.
- Business Quant data shows ONC's Cash & Equivalents at $4.8 billion in Q1 2026, $4.5 billion in Q4 2025, and $4.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 1.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.10 Bn |
| Mar 31, 2026 | 4.79 Bn |
| Dec 31, 2025 | 4.55 Bn |
| Sep 30, 2025 | 4.04 Bn |
| Jun 30, 2025 | 2.76 Bn |
| Mar 31, 2025 | 2.52 Bn |
| Dec 31, 2024 | 2.63 Bn |
| Sep 30, 2024 | 2.70 Bn |
| Jun 30, 2024 | 2.59 Bn |
| Mar 31, 2024 | 2.79 Bn |
| Dec 31, 2023 | 3.17 Bn |
| Sep 30, 2023 | 3.07 Bn |
| Jun 30, 2023 | 3.41 Bn |
| Mar 31, 2023 | 3.54 Bn |
| Dec 31, 2022 | 3.87 Bn |
| Sep 30, 2022 | 191,000.00 |
| Jun 30, 2022 | 4.53 Bn |
| Mar 31, 2022 | 330,000.00 |
| Dec 31, 2021 | 328,000.00 |
| Sep 30, 2021 | 1.38 Bn |